Bayer AG is packing more cancer drugs into its pipeline to gain a bigger share of the almost $100 billion global market for such treatments.

Known for Aspirin and the blood thinner Xarelto, Germany’s most valuable company had no cancer treatments on the market a decade ago. By the end of this one, Bayer may have as many as five if its research plans pay off. The company has more than doubled the number of cancer medicines in development in the last three years, including treatments that marry radiation and biologics.


Source: BioSpace